Amit Mandoli,Ph. D

PDF Duke-NUS Medical School, Singapore

PDF Radboud Institute for Molecular Life Sciences (RIMLS), Nijmegen, The Netherlands

Ph.D. University of Padova, Padova, Italy

Dr. Amit Mandoli

Assistant Professor

Tele : +91 79 66745555

E-mail :,

Research Interest

Dr.Amit Mandoli research focuses on using high-throughput assays to identify unique molecular processes that are involved in cancer, and translate the fundamental insights gained through his research into diagnostics and drug discovery processes. Core areas of his research are: Genomics, Functional Genomics, Epigenetics (ChIP-seq), Chromatin interactions (HiC, 4C, Hi-ChIP), Transcriptomics (RNA-seq), Gene regulation, Next generation sequencing (NGS) technologies, CRISPR-Cas9 genome editing, Mass-spec based high-throughput proteomics, NGS analysis and development of novel in vitro cancer model systems.


  • February 2020 -Present:
    Assistant Professor, NIPER- Ahmedabad, Palaj, Gandhinagar
  • February 2018 – February 2020:
    Senior Researcher, Duke-NUS Medical School, Singapore
  • March 2017 – October 2017:
    Postdoc scientist,Institute for cancer research, Oslo University Hospital, Norway .
  • January 2012 – December 2016:
    Postdoc scientist, Radboud Institute for Molecular Life Sciences (RIMLS), Nijmegen, The Netherlands



  • Postdoc scientist funded by Dutch Cancer Society
  • Prestigious International PhD grant for foreign nationals by Italian government and CARIPARO
  • CSIR diamond jubilee research interns award
  • MSc Biotechnology Scholarship from the Department of Biotechnology (DBT)


  • Ambika Chamoli, Abhishek S.Gosavi, Urjita P.Shirwadkar, Khushal V.Wangdale, Santosh Kumar Behera, Nawneet Kumar Kurrey, Kiran Kalia, Mandoli A. (2021). Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics, Oral Oncology. 121, 105451.
  • Sagar Salave, Sonali Jain, Ambika Chamoli, Mandoli A,, Ravi Shah, Kiran Kalia, Derajram Benival. (2020). Role Of Biologicals For Combating Covid-19: A Systematic Review, World Journal Of Pharmacy And Pharmaceutical Sciences,9(12), 456-484. DOI: 10.20959/wjpps202012-17770
  • Cordonnier G,Mandoli A,, Cagnard N, et al. CBFβ-SMMHC Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid. Leukemia. Cell Rep. 2020;30(2):299–307.e3 (IF: 8.1)
  • Tijchon E, Yi G,Mandoli A,, et al. The acute myeloid leukemia associated AML1-ETO fusion protein alters the transcriptome and cellular progression in a single-oncogene expressing in vitro induced pluripotent stem cell based granulocyte differentiation model. PLoS One. 2019;14(12):e0226435 (IF: 2.26)
  • Ooi WF, Nargund,Mandoli A,, Lim KJ, et al. Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma. Gut. 2019;gutjnl-2018-317612 (IF: 17)
  • Yi G,Mandoli A, Jussen L, et al. CBFβ-MYH11 interferes with megakaryocyte differentiation via modulating a gene program that includes GATA2 and KLF1. Blood Cancer J. 2019;9(3):33 (IF: 8.1)
  • Yi G, Wierenga ATJ, Petraglia F, et al. Chromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness Phenotypes. Cell Rep. 2019;26(4):1059–1069.e6 (IF: 7.2)
  • Cordonnier G, Mandoli A, Radhouane A, et al. CBFβ-SMMHC regulates ribosomal gene transcription and alters ribosome biogenesis. Leukemia. 2017;31(6):1443–1446 (IF: 12.1 )
  • Prange KHM,Mandoli A, Kuznetsova T, et al. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia. Oncogene. 2017;36(23):3346–3356 (IF: 6.85)
  • Singh AA,Mandoli A, Prange KH, Laakso M, Martens JH. AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis. Oncotarget. 2017;8(8):12855–12865 (IF: 5.1)
  • Mandoli A, Singh AA, Prange KHM, et al. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs. Cell Rep. 2016;17(8):2087–2100 (IF: 7.2)
Complete list
Go to Navigation